Verrica Pharmaceuticals (VRCA) Cash from Operations (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Cash from Operations of 9200000.0 for Q1 2026, up 27.43% year-over-year from 7219784.57 in Q1 2025, and down 100.0% quarter-over-quarter from 4600000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Cash from Operations (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Cash from Operations history runs 10 years deep, the most recent figure standing at 9200000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 27.43% year-over-year to 9200000.0; the TTM figure through Mar 2026 stood at 14123000.0 (up 73.68% YoY), while the FY2025 annual figure was 17600000.0, up 71.11% from the prior year.
- Cash from Operations for Q1 2026 stood at 9200000.0, down from 4600000.0 in the prior quarter.
- The five-year high for Cash from Operations was 9721000.0 in Q3 2025, with the low at 19947000.0 in Q1 2024.
- The 5-year median for Cash from Operations is 8558000.0 (2024), against an average of 8526705.88.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations sank 911.56% in 2023, then jumped 213.59% in 2025.
- Verrica Pharmaceuticals' Cash from Operations stood at 4954000.0 in 2022, then plunged by 192.83% to 14507000.0 in 2023, then declined by 10.73% to 16064000.0 in 2024, then soared by 71.36% to 4600000.0 in 2025, then sank by 100.0% to 9200000.0 in 2026.
- Business Quant data shows VRCA's Cash from Operations at 9200000.0 in Q1 2026, 4600000.0 in Q4 2025, and 9721000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -9.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.24 Mn |
| Jun 30, 2026 | -9.24 Mn |
| Mar 31, 2026 | -9.20 Mn |
| Mar 31, 2026 | -9.20 Mn |
| Dec 31, 2025 | -4.60 Mn |
| Dec 31, 2025 | -4.60 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Jun 30, 2025 | -10.04 Mn |
| Jun 30, 2025 | -10.04 Mn |
| Mar 31, 2025 | -12.68 Mn |
| Mar 31, 2025 | -12.68 Mn |
| Dec 31, 2024 | -16.06 Mn |
| Dec 31, 2024 | -16.06 Mn |
| Sep 30, 2024 | -8.56 Mn |
| Sep 30, 2024 | -8.56 Mn |
| Jun 30, 2024 | -16.36 Mn |
| Jun 30, 2024 | -16.36 Mn |
| Mar 31, 2024 | -19.95 Mn |
| Mar 31, 2024 | -19.95 Mn |